

VIRGINIA:

BEFORE THE BOARD OF MEDICINE

IN RE: KENNETH D. HANSEN, M.D.
License No. 0101-038833

ORDER

In accordance with Sections 54.1-2919 and 9-6.14:11 of the Code of Virginia (1950), as amended ("Code"), an informal conference was held with Kenneth D. Hansen, M.D., on February 11, 2000, in Richmond, Virginia. Members of the Virginia Board of Medicine ("Board") serving on the Informal Conference Committee ("Committee") were: Harry C. Beaver, M.D., Chairman; Jeffrey R. Vaughn, M.D.; and Connell J. Trimber, M.D. Dr. Hansen appeared personally and was not represented by legal counsel. The purpose of the informal conference was to review Dr. Hansen's compliance with the terms and conditions imposed upon his license to practice medicine in Virginia by Order of the Board entered October 23, 1998, and modified June 22, 1999, as set forth in a Notice of Informal Conference dated January 19, 2000.

FINDINGS OF FACT

Now, having properly considered the information and statements presented, the Committee makes the following Findings of Fact:

1. By Order of the Board entered April 4, 1997, the license of Dr. Hansen was summarily suspended based upon his impairment due to substance abuse. By Order of the Board entered October 23, 1998, the suspension of the license of Dr. Hansen was terminated, and his license was placed on indefinite probation on terms and conditions. By letter of the Board dated June 22, 1999, Terms #1 and #2 of the Order of October 23, 1998, were modified to reflect that Dr. Hansen's monitoring contract with the Medical Society of Virginia's Physicians' Health and Effectiveness Committee ("PHEC") had been transferred to Virginia Monitoring, Inc. Health Practitioners' Intervention Program ("HPIP").

Kenneth D. Hansen, M.D.

2. Dr. Hansen is compliant with the terms and conditions of the Board's Order entered October 23, 1998, as modified on June 22, 1999.

CONCLUSIONS OF LAW


Based on the foregoing Findings of Fact, the Committee concludes that Dr. Hansen is properly before it and it is responsible for reviewing and approving all information relative to the terms of the Board Order entered October 23, 1998, as modified June 22, 1999.

ORDER

WHEREFORE, based on the foregoing Findings of Fact and Conclusions of Law, it is hereby ORDERED that the INDEFINITE PROBATION imposed upon Dr. Hansen's license to practice medicine is TERMINATED, and that his license be, and hereby is, REINSTATED to a full and unrestricted status with all attendant rights and privileges.

Pursuant to Section 9-6.14:14 of the Code, the signed original of this Order shall remain in the custody of the Department of Health Professions as a public record, and shall be made available for public inspection and copying upon request.

FOR THE BOARD



William L. Harp, M.D.
Executive Director
Virginia Board of Medicine

Entered: 2/16/2000

PLLAHANSEN65IFCORD.DOC

VIRGINIA:

BEFORE THE BOARD OF MEDICINE

**IN RE: KENNETH D. HANSEN, M.D.
 LICENSE NO. 0101-038833**

ORDER OF SUMMARY SUSPENSION

Pursuant to Sections 54.1-2920 and 54.1-105 of the Code of Virginia (1950), as amended ("Code"), the Virginia Board of Medicine ("Board") met by telephone conference call on April 4, 1997, to receive and act upon certain investigative information indicating that Kenneth D. Hansen, M.D., may have violated certain laws relating to the practice of medicine in the Commonwealth of Virginia. Prior to this meeting, a good faith effort to assemble a quorum of the Board in person was made, but was not successful, and the six members of the Executive Committee available for consultation unanimously agreed on April 4, 1997, that the continued practice of medicine by Dr. Hansen constitutes a substantial danger to the public health and safety. The meeting was convened before twelve members of the Board, constituting a quorum, by a telephone conference call. The matter was presented by Assistant Attorney General Frank W. Pedrotty. Also participating in the conference call was Assistant Attorney General Lynne R. Fleming, Board counsel; Regional Investigative Supervisor William Addison Hurst and Senior Investigator Charles F. Johnson. Dr. Hansen did not participate in the conference call.

Upon hearing the evidence presented, the Board unanimously determined that the continued practice of Kenneth D. Hansen, M.D., constitutes a substantial danger to the public health and safety, in that Dr. Hansen may be unable to practice medicine with reasonable skill and safety to his patients and the public based upon illness and/or substance abuse. Specifically:

- a. In approximately 1995, staff at Arlington Hospital, Arlington, Virginia, observed a change in Dr. Hansen's behavior and demeanor, in that he exhibited mood swings, made bizarre comments, talked in a loud voice, exhibited irritability and forgetfulness, and arrived as much as one (1) hour late for scheduled surgeries. Staff observed that Dr. Hansen sweated profusely and his hands trembled while performing surgery. In addition, Dr. Hansen's face and hands were swollen, he took longer than usual to complete certain surgical procedures, and he often disappeared from the operating room between surgeries.

Order of Summary Suspension - Dr. Hansen

- b. On or about September 3, 1996, when interviewed by an investigator of the Department of Health Professions, Dr. Hansen admitted that, in approximately 1992, he began to abuse Dalgan (dezocine - Schedule VI) by self-administering one (1) 10mg Dalgan injection nightly. By the time he entered treatment, Dr. Hansen's Dalgan use had escalated to three (3) or four (4) 10mg Dalgan injections every night. Dr. Hansen obtained Dalgan from a number of sources including the Arlington Hospital pharmacy, several local pharmacies and several drug wholesalers.
- c. On or about September 3, 1996, when interviewed by an investigator of the Department of Health Professions, Dr. Hansen admitted that, in approximately 1995, he began to self-administer Prozac (Schedule VI) on a daily basis for his self-diagnosed depression. Medical records indicate that Dr. Hansen self-administered 40mg Prozac, twice per day, until he discontinued its use in approximately October 1995. Further, Dr. Hansen admitted that he diverted Prozac from the stock of drug samples designated to be sent to an agency in Jamaica.
- d. In approximately November or December 1995, the Medical Society of Virginia's Physicians' Health and Effectiveness Committee ("MSOV PHEC") met with Dr. Hansen to conduct an intervention. As a result of the intervention, Dr. Hansen agreed to undergo an assessment at Talbott Marsh Recovery System ("Talbott Marsh"), Atlanta, Georgia, which he entered on or about January 3, 1996, and where he received a diagnosis of opiate dependence. Dr. Hansen underwent several days of treatment, but left the program early and against medical advice.
- e. In approximately February 1996, Dr. Hansen's surgical privileges at Arlington Hospital were informally suspended until he completed his treatment program.
- f. On or about February 6, 1996, Dr. Hansen entered an intensive out-patient treatment program with Rodney V. Burbach, M.D., Suburban Hospital, Bethesda, Maryland.
- g. On or about March 11, 1996, upon the MSOV PHEC's referral, Dr. Hansen entered the Minnesota Professional Assessment Program at Abbott Northwestern Hospital, Minneapolis, Minnesota. Upon admission, Dr. Hansen's urine drug screen was positive for Diphenhydramine

Order of Summary Suspension - Dr. Hansen

(Schedule VI). Dr. Hansen was diagnosed with opioid dependence and successfully completed his treatment program. He was discharged on March 15, 1996, and subsequently entered a treatment program at Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois. Dr. Hansen successfully completed the four-week program and was discharged on or about April 25, 1996.

- h. On or about May 1, 1996, Dr. Hansen entered into an Advocacy and Aftercare Agreement with the MSOV PHEC.
- i. Dr. Hansen's July 26, 1996, drug screen revealed a presumptive positive for ephedrines, and his December 24, 1996, drug screen revealed a presumptive positive for Phenylpropanolamine.
- j. On or about January 15, 1997, Arlington Hospital staff observed that Dr. Hansen was unshaven, his hair was uncombed, he arrived late for a scheduled surgery, his eyes were "glassy," his speech was slurred and his face and hands appeared swollen. Further, while performing cataract surgery on Patient A, Dr. Hansen exhibited impaired behavior in that his hands trembled during the surgery and he had difficulty operating the cautery/phacoemulsification machine, a piece of equipment that he had used often during the past five (5) years. In addition, although the cover of the intraocular lens ("IOL") container was not opened, Dr. Hansen repeatedly attempted to remove the IOL from the container. Although the procedure was visible on a television monitor, Dr. Hansen stopped the surgery several times in order to invite a visiting physician to look through the microscope. Staff observed that Patient A incurred excessive bleeding during the surgery. As a result of this incident, Dr. Hansen's surgical privileges at Arlington Hospital were suspended.
- k. Dr. Hansen appeared to be in compliance with his MSOV PHEC agreement, in that all of his urine samples for drug screening were provided on schedule and the results of all screens were negative. In addition, on or about January 24, 1997, Dr. Hansen's counselors from Suburban Hospital reported that they saw no evidence of a relapse and that he was doing well in his

Order of Summary Suspension - Dr. Hansen

recovery program. On or about February 2, 1997, Rodney V. Burbach, M.D., Dr. Hansen's treating physician, reported that Dr. Hansen was committed to abstinence and to his recovery. On or about February 10, 1997, Dr. Hansen's operating privileges at Arlington Hospital were restored.

- i. During the period September 5, 1996, through March 27, 1997, Dr. Hansen purchased, from not less than three (3) drug wholesalers, the following:
 - 1) 225 vials of Dalgan 100mg/10ml and 75 vials Dalgan 20mg/2ml;
 - 2) 178 vials of Diphenhydramine 500mg/10ml and 5 vials of Diphenhydramine 300/30ml;
 - 3) 160 ampuls of Buprenex 0.3mg/1ml (buprenorphinehydrochloride - Schedule V).
- m. On or about March 28, 1997, pursuant to a recommendation of a MSOV PHEC panel, Dr. Hansen entered Talbott Marsh for a comprehensive addictive disease and psychiatric assessment. On or about April 1, 1997, Dr. Hansen's treating physician, Phillip O. Wilson, M.D., observed that Dr. Hansen exhibited strange behavior, slurred speech and had a flat affect. A search of Dr. Hansen's room and person uncovered contraband that included syringes, bottles of bacteriostatic water and a rubber penis connected by tubing to a bottle of urine. After repeated questioning, Dr. Hansen admitted he had been self-administering Dalgan, but he refused to reveal for how long and how much he had been using. Out of fear that he was a danger to himself, Dr. Hansen was committed to the psychiatric unit. On or about April 2, 1997, Talbott Marsh staff notified a member of the MSOV PHEC that Dr. Hansen had left the facility and his whereabouts were unknown. As a result, Dr. Hansen is out of compliance with his agreement with the MSOV PHEC. It is Dr. Wilson's opinion that Dr. Hansen is in chemical relapse, in need of continued treatment and that he is unable to practice medicine with reasonable skill and safety.


Order of Summary Suspension - Dr. Hansen

ORDER

WHEREFORE, it is hereby ORDERED that the license of Kenneth D. Hansen, M.D., to practice medicine and surgery in the Commonwealth of Virginia be and hereby is **SUMMARILY SUSPENDED**, simultaneously with the institution of proceedings for a formal hearing in this matter. Said hearing shall be scheduled within a reasonable time from the date of this summary suspension.

Pursuant to Section 9-6.14:14 of the Code, the signed original of this Order shall remain in the custody of the Virginia Board of Medicine as a public record and shall be made available for public inspection and copying upon request.

FOR THE BOARD


Warren W. Koontz, M.D.
Executive Director
Virginia Board of Medicine

ENTERED: April 4, 1987

VIRGINIA

BEFORE THE BOARD OF MEDICINE

**IN RE: KENNETH D. HANSEN, M.D.
 LICENSE NO. 0101-038833**

ORDER

In accordance with the provisions of Sections 54.1-2408.1, 54.1-110, 54.1-2920 and 9-6.14:12 of the Code of Virginia (1950), as amended ("Code"), a formal administrative hearing was convened before the Virginia Board of Medicine ("Board"), on October 9, 1998, in Richmond, Virginia. The purpose of the hearing was to receive and act upon evidence that Kenneth D. Hansen, M.D., may have violated certain laws governing the practice of medicine in Virginia, as set forth in a Notice of Hearing and Amended Statement of Particulars ("Notice") dated April 21, 1997.

Pursuant to Sections 54.1-2400 and 9-6.14:14.1F of the Code, the hearing was held before a panel of the Board with the a member of the Board presiding. Dr. Hansen appeared personally and was represented by Michael L. Goodman, Esquire, and Kathryn Freeman-Jones, Esquire. Lynne R. Fleming, Assistant Attorney General, was present as legal counsel for the Board. The Commonwealth's case was presented by James L. Banning, Director, Administrative Proceedings Division, Department of Health Professions. As a preliminary matter, Mr. Goodman stated that while Dr. Hansen neither admits nor denies the allegations, he would not actively contest the allegations in the Notice for purposes of the hearing. Mr. Banning stated he had no objections to this stipulation and the Board determined to proceed accordingly. The proceedings were recorded by a certified court reporter.

FINDINGS OF FACT

Now, having properly considered the evidence and testimony presented, the Board makes the following Findings of Fact:

1. In approximately 1995, staff at Arlington Hospital, Arlington, Virginia, observed a change in

Dr. Hansen

Dr. Hansen's behavior and demeanor, in that he exhibited mood swings, made bizarre comments, talked in a loud voice, exhibited irritability and forgetfulness, and arrived as much as one (1) hour late for scheduled surgeries. Staff observed that Dr. Hansen sweated profusely and his hands trembled while performing surgery. In addition, Dr. Hansen's face and hands were swollen, he took longer than usual to complete certain surgical procedures, and he often disappeared from the operating room between surgeries.

2. On or about September 3, 1996, when interviewed by an investigator of the Department of Health Professions, Dr. Hansen admitted that, in approximately 1992, he began to abuse Dalgan (dezocine, Schedule VI) by self-administering one (1) 10mg Dalgan injection nightly. By the time he entered treatment, Dr. Hansen's Dalgan use had escalated to three (3) or four (4) 10mg Dalgan injections every night. Dr. Hansen obtained Dalgan from a number of sources including the Arlington Hospital pharmacy, several local pharmacies and several drug wholesalers.

3. On or about September 3, 1996, when interviewed by an investigator of the Department of Health Professions, Dr. Hansen admitted that, in approximately 1995, he began to self-administer Prozac (Schedule VI) on a daily basis for his self-diagnosed depression. Medical records indicate that Dr. Hansen self-administered 40mg Prozac, twice per day, until he discontinued its use in approximately October 1995. Further, Dr. Hansen admitted that he diverted Prozac from the stock of drug samples designated to be sent to an agency in Jamaica.

4. In approximately November or December 1995, the Medical Society of Virginia's Physicians' Health and Effectiveness Committee ("MSOV PHEC") met with Dr. Hansen to conduct an intervention. As a result of the intervention, Dr. Hansen agreed to undergo an assessment at Talbott Marsh Recovery System ("Talbott Marsh"), Atlanta, Georgia, which he entered on or about January 3, 1996, and where he received a diagnosis of opiate dependence. Dr. Hansen underwent several days of treatment, but left the program early and against medical advice.

Dr. Hansen

5. In approximately February 1996, Dr. Hansen's surgical privileges at Arlington Hospital were informally suspended until he completed his treatment program.
6. On or about February 6, 1996, Dr. Hansen entered an intensive out-patient treatment program with Rodney V. Burbach, M.D., Suburban Hospital, Bethesda, Maryland.
7. On or about March 11, 1996, upon the MSOV PHEC's referral, Dr. Hansen entered the Minnesota Professional Assessment Program at Abbott Northwestern Hospital, Minneapolis, Minnesota. Upon admission, Dr. Hansen's urine drug screen was positive for diphenhydramine (Schedule VI). Dr. Hansen was diagnosed with opioid dependence and successfully completed his treatment program. He was discharged on March 15, 1996, and subsequently entered a treatment program at Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois. Dr. Hansen successfully completed the four-week program and was discharged on or about April 25, 1996.
8. On or about May 1, 1996, Dr. Hansen entered into an Advocacy and Aftercare Agreement with the MSOV PHEC.
9. Dr. Hansen's July 26, 1996, drug screen revealed a presumptive positive for ephedrine, and his December 24, 1996, drug screen revealed a presumptive positive for phenylpropanolamine.
10. On or about January 15, 1997, Arlington Hospital staff observed that Dr. Hansen was unshaven, his hair was uncombed, he arrived late for a scheduled surgery, his eyes were "glassy," his speech was slurred and his face and hands appeared swollen. Further, while performing cataract surgery on Patient A, Dr. Hansen exhibited impaired behavior in that his hands trembled during the surgery and he had difficulty operating the cautery/phacoemulsification machine, a piece of equipment that he had used often during the past five (5) years. In addition, although the cover of the intraocular lens ("IOL") container was not opened, Dr. Hansen repeatedly attempted to remove the IOL from the container. Although the procedure was visible on a television monitor, Dr. Hansen stopped the surgery several times in order to invite a visiting physician to look through the

Dr. Hansen

microscope. Staff observed that Patient A incurred excessive bleeding during the surgery. As a result of this incident, Dr. Hansen's surgical privileges at Arlington Hospital were suspended.

11. Dr. Hansen appeared to be in compliance with his MSOV PHEC agreement, in that all of his urine samples for drug screening were provided on schedule and the results of all screens were negative. In addition, on or about January 24, 1997, Dr. Hansen's counselors from Suburban Hospital reported that they saw no evidence of a relapse and that he was doing well in his recovery program. On or about February 2, 1997, Rodney V. Burbach, M.D., Dr. Hansen's treating physician, reported that Dr. Hansen was committed to abstinence and to his recovery. On or about February 10, 1997, Dr. Hansen's operating privileges at Arlington Hospital were restored.

12. During the period September 5, 1996, through March 27, 1997, Dr. Hansen purchased, from not less than three (3) drug wholesalers, the following:

- a) 225 vials of Dalgan 100mg/10ml and 75 vials Dalgan 20mg/2ml;
- b) 178 vials of diphenhydramine 500mg/10ml and 5 vials of diphenhydramine 300/30ml;
- c) 160 ampuls of Buprenex 0.3mg/1ml (buprenorphinehydrochloride, Schedule V).

13. On or about March 28, 1997, pursuant to a recommendation of a MSOV PHEC panel, Dr. Hansen entered Talbott Marsh for a comprehensive addictive disease and psychiatric assessment. On or about April 1, 1997, Dr. Hansen's treating physician, Phillip O. Wilson, M.D., observed that Dr. Hansen exhibited strange behavior, slurred speech and had a flat affect. A search of Dr. Hansen's room and person uncovered contraband that included syringes, bottles of bacteriostatic water and a rubber penis connected by tubing to a bottle of urine. After repeated questioning, Dr. Hansen admitted he had been self-administering Dalgan, but he refused to reveal for how long and how much he had been using. Out of fear that he was a danger to himself, Dr. Hansen was committed to the psychiatric unit. On or about April 2, 1997, Talbott Marsh staff notified a member of the MSOV PHEC that Dr. Hansen had left the facility and his whereabouts were unknown. As a

Dr. Hansen

result, Dr. Hansen was out of compliance with his agreement with the MSOV PHEC. It was Dr. Wilson's opinion that Dr. Hansen was in chemical relapse, in need of continued treatment and that he was unable to practice medicine with reasonable skill and safety.

14. From June 6, 1997, to September 5, 1997, Dr. Hansen received treatment for chemical dependency at Rush Behavioral Health Center ("Rush"), Chicago, Illinois. According to Paul Feldman, M.D., Medical Director, Dr. Hansen made substantial progress in treatment. Subsequent to discharge from Rush, outpatient treatment recommendations included monitoring by the MSOV PHEC, weekly attendance at physician support group, individual and marital therapy, urine monitoring, and maintenance of a 12-step program.

15. Joan Pickett, L.P.C. and Certified Addiction Counselor, testified that she is familiar with Dr. Hansen's recovery through her capacity as a group facilitator within the MSOV PHEC beginning in September 1996. By letter dated October 9, 1998, Ms. Pickett stated that she is "completely confident" in Dr. Hansen's recovery, that his recovery is "solid" and that she believes he is "ready to take up his responsibilities again."

16. Michael Cohen, M.D., Vice-Chairman, MSOV PHEC, testified that Dr. Hansen's Aftercare Agreement with the MSOV PHEC will run through March 2003 and, for the entire duration of that period, Dr. Hansen will be required to be in a monitoring group. By letter dated October 7, 1998, Dr. Cohen stated that Dr. Hansen has been an "exemplary patient" who has entered wholeheartedly into all aspects of the recovery process. Dr. Cohen further noted that Dr. Hansen is "well-suited to resume his professional duties."

17. Dr. Hansen testified that he attends five Alcoholics Anonymous/Narcotics Anonymous meetings per week and weekly meetings of the International Association of Doctors in Alcoholics Anonymous, in which he has assumed a leadership position. His sobriety date from all controlled substances and alcohol is August 1, 1997.

18. By letter dated October 6, 1998, Paul Feldman, M.D., Medical Director, Rush, indicated that based on his progress, Dr. Hansen is able to return to practice under the following recommended conditions:

Dr. Hansen

- a. Continue to participate in formal monitoring to include weekly physician support group, urine monitoring to include testing for mixed opioid agonist/antagonist, e.g., Nubain and Dalgan.
- b. Continue to attend no less than three 12-step meetings weekly, and have a sponsor.
- c. Obtain a physician practice monitor, who may review Dr. Hansen's charts to provide feedback and give quarterly reports to the Board.
- d. Keep no mood-altering substances in his practice or workplace and not personally handle or administer such substances.

19. Dr. Hansen testified that he has received approximately twenty (20) hours of Continuing Medical Education in refractive surgery. Further, Dr. Hansen testified that he reads medical journals approximately four (4) hours a week.

20. Dr. Hansen plans to re-enter practice in this former private practice setting and expects initially to see patients two (2) or three (3) days per week. He plans to apply for hospital privileges, but to initially serve only as an assistant to the principal surgeon.

CONCLUSIONS OF LAW

Based upon the foregoing Findings of Fact, the Board concludes that Kenneth D. Hansen, M.D., is in violation of Section 54.1-2915.A(2) and (3), as further defined in Sections 54.1-2914.A(9), (10) and (11) of the Code.

ORDER

Based on the foregoing Findings of Fact and Conclusions of Law, it is hereby ORDERED that the SUSPENSION placed on Dr. Hansen's license by Order dated April 21, 1997, is hereby TERMINATED, and his license is placed on INDEFINITE PROBATION on the following terms and conditions:

Dr. Hansen

1. Dr. Hansen shall abide by the terms of his March 3, 1998, Aftercare Agreement with the MSOV PHEC and any and all addenda thereto. Dr. Hansen shall cause progress reports from the MSOV PHEC to be submitted to the Board on a calendar quarterly basis.
2. Dr. Hansen shall sign an authorization providing for unrestricted communication between and among the Board, the MSOV PHEC, and Dr. Hansen's current or former treating or evaluating practitioners (including, but not limited to, substance abuse evaluations or treatment records from substance abuse treatment facilities).
3. Dr. Hansen is prohibited from maintaining any mood-altering substances, including samples, in his office. He shall not personally handle or administer such substances.
4. Dr. Hansen shall engage a physician, approved by the Board, to monitor his medical practice. The monitor shall perform a detailed review of Dr. Hansen's medical records at least once a month, in accordance with a protocol to be provided by the Board. Dr. Hansen shall cause the monitor to provide a detailed and informative report to the Board on a calendar quarterly basis.
5. Within one (1) year of entry of this Order, Dr. Hansen shall successfully complete fifty (50) hours of Category I, AMA approved continuing education ("CE") in ophthalmology. All CE shall be approved in advance of registration by the Board's Executive Director.
6. Dr. Hansen shall maintain a course of conduct in his practice of medicine commensurate with the requirements of Title 54.1, Chapter 29 of the Code and all laws of the Commonwealth.
7. Dr. Hansen shall cooperate with the Board and the Department of Health Professions in the investigation or inspection of his practice to verify that he is in compliance with this Order.
8. Dr. Hansen shall notify the Executive Director of the Board by certified mail of any change of address within ten days of such occurrence.

Dr. Hansen


9. In approximately one (1) year, Dr. Hansen shall be noticed to appear before an informal conference committee of the Board. Said committee shall provide the ongoing monitoring of Dr. Hansen's Order, determine the frequency of further appearance by Dr. Hansen before it, and shall serve as the instrument of the Board responsible for reviewing and approving all information relative to the terms and conditions of this Order, except as noted above.

Violation of this Order shall constitute grounds for the revocation of the license of Dr. Hansen. In the event Dr. Hansen violates any of the terms and conditions of this Order, an administrative proceeding may be convened to determine whether the license of Dr. Hansen should be revoked.

As provided by Rule 2A:2 of the Supreme Court of Virginia, Dr. Hansen has thirty (30) days from the date of service (the date he actually received this decision or the date it was mailed to him, whichever occurred first), within which to appeal this decision by filing a Notice of Appeal with Warren W. Koontz, M.D., Executive Director, Board of Medicine, Department of Health Professions, 6606 W. Broad Street, 4th Floor, Richmond, Virginia 23230-1717. In the event that this decision is served by mail, three (3) days are added to that period.

Pursuant to Section 9-6.14:14 of the Code, the signed original of this Order shall remain in the custody of the Department of Health Professions as a public record, and shall be made available for public inspection and copying upon request.

FOR THE BOARD



Warren W. Koontz, M.D.
Executive Director
Virginia Board of Medicine

ENTERED: 10-23-98
nunc pro tunc